Antihemophilic factor (recombinant) is a Recombinant Protein owned by Takeda Pharmaceutical, and is involved in 2 clinical trials, which were completed.

Antihemophilic factor is specific coagulation factor deficient in patients with haemophilia A (congenital factor VIII). Hemophilia A is a bleeding disorder of genetic origin, characterized by bleeding that may occur spontaneously or after minor trauma. Factor VIII involved in coagulation. As a cofactor for factor IX, accelerating the conversion of factor X to factor Xa. Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed. Factor VIII activity is significantly reduced in patients with hemophilia A and replacement therapy is necessary.

The revenue for Antihemophilic factor (recombinant) is expected to reach a total of $1.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Antihemophilic factor (recombinant) NPV Report.

Antihemophilic factor (recombinant) is currently owned by Takeda Pharmaceutical.

Antihemophilic factor (recombinant) Overview

Antihemophilic factor (recombinant) (Recombinate) is a glycoprotein synthesized by a genetically engineered Chinese Hamster Ovary (CHO) cell line. It is formulated as a sterile onpyrogenic, off-white to faint yellow, injectable lyophilized powder preparation of concentrated recombinant Factor VIII for intravenous route of administration. Recombinate is also indicated in the perioperative management of patients with hemophilia A (classical hemophilia).

Takeda Pharmaceutical Overview

Takeda Pharmaceutical (Takeda) is a research-based pharmaceutical company which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, oncology, neuroscience, vaccines, and plasma-derived therapies. Takeda has facilities in Japan, Argentina, Brazil, Mexico, the US, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China and India, Canada among others. It markets products directly and through a network of wholesale distributors, retail chains and other purchasing groups worldwide. Takeda has partnership with academic institutions, small biotech, and large pharmaceutical companies. It has presence in the Americas, Europe, and Asia, among others. Takeda is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY3,569,006 million for the fiscal year ended March 2022 (FY2022), an increase of 11.6% over FY2021. In FY2022, the company’s operating margin was 12.5%, compared to an operating margin of 18.8% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 11.8% in FY2021. The company reported revenues of JPY1,002,307 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.

Quick View – Antihemophilic factor (recombinant)

Report Segments
  • Innovator (NME)
Drug Name
  • Antihemophilic factor (recombinant)
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hematological Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.